Needham & Company LLC Reiterates “Buy” Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They currently have a $28.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 87.17% from the company’s […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They currently have a $28.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 87.17% from the company’s […]